Abstract
Aspirin has been associated with a reduced risk of colorectal cancer. With specific reference to urological cancers, a protective role for aspirin has been suggested for prostate cancer, but data for cancers of the bladder and kidney have been limited and inconsistent. Epidemiological evidence suggests that prostate cancer risk is reduced by 10% in regular aspirin users, with similar risk reductions reported in both case-control and cohort studies, and for both slow-growing and aggressive cancers. However, risk estimates were significantly heterogeneous and there was no relationship between risk reduction and frequency, dose or duration of use. Thus, inference for causality and public health implications remain far from conclusive. Although a few case-control studies have reported a favorable effect of aspirin on bladder cancer, most investigations did not find any meaningful association. A modest nonsignificant increased risk was reported for kidney cancer. Such excess risk, however, might be due to exposure to phenacetin-containing analgesics, which have been reported to increase renal cell cancer risk.
| Original language | English |
|---|---|
| Pages (from-to) | 102-110 |
| Number of pages | 9 |
| Journal | Nature Reviews Urology |
| Volume | 9 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2012 |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Aspirin and urologic cancer risk : An update. / Bosetti, Cristina; Rosato, Valentina; Gallus, Silvano; La Vecchia, Carlo.
In: Nature Reviews Urology, Vol. 9, No. 2, 02.2012, p. 102-110.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Aspirin and urologic cancer risk
T2 - An update
AU - Bosetti, Cristina
AU - Rosato, Valentina
AU - Gallus, Silvano
AU - La Vecchia, Carlo
PY - 2012/2
Y1 - 2012/2
N2 - Aspirin has been associated with a reduced risk of colorectal cancer. With specific reference to urological cancers, a protective role for aspirin has been suggested for prostate cancer, but data for cancers of the bladder and kidney have been limited and inconsistent. Epidemiological evidence suggests that prostate cancer risk is reduced by 10% in regular aspirin users, with similar risk reductions reported in both case-control and cohort studies, and for both slow-growing and aggressive cancers. However, risk estimates were significantly heterogeneous and there was no relationship between risk reduction and frequency, dose or duration of use. Thus, inference for causality and public health implications remain far from conclusive. Although a few case-control studies have reported a favorable effect of aspirin on bladder cancer, most investigations did not find any meaningful association. A modest nonsignificant increased risk was reported for kidney cancer. Such excess risk, however, might be due to exposure to phenacetin-containing analgesics, which have been reported to increase renal cell cancer risk.
AB - Aspirin has been associated with a reduced risk of colorectal cancer. With specific reference to urological cancers, a protective role for aspirin has been suggested for prostate cancer, but data for cancers of the bladder and kidney have been limited and inconsistent. Epidemiological evidence suggests that prostate cancer risk is reduced by 10% in regular aspirin users, with similar risk reductions reported in both case-control and cohort studies, and for both slow-growing and aggressive cancers. However, risk estimates were significantly heterogeneous and there was no relationship between risk reduction and frequency, dose or duration of use. Thus, inference for causality and public health implications remain far from conclusive. Although a few case-control studies have reported a favorable effect of aspirin on bladder cancer, most investigations did not find any meaningful association. A modest nonsignificant increased risk was reported for kidney cancer. Such excess risk, however, might be due to exposure to phenacetin-containing analgesics, which have been reported to increase renal cell cancer risk.
UR - http://www.scopus.com/inward/record.url?scp=84857030611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857030611&partnerID=8YFLogxK
U2 - 10.1038/nrurol.2011.219
DO - 10.1038/nrurol.2011.219
M3 - Article
VL - 9
SP - 102
EP - 110
JO - Nature Reviews Urology
JF - Nature Reviews Urology
SN - 1759-4812
IS - 2
ER -